Medicago Awarded $21 million from the US Department of Defense
Medicago Awarded $21 million from the US Department of Defense
Medicago USA Inc. (Raleigh, NC), a wholly owned subsidiary of Medicago Inc. (Quebec City, Canada), a clinical-stage biotechnology company focused on developing vaccines based on proprietary manufacturing technologies and virus-like particles (VLPs), has been awarded a $21 million grant from the Defense Advanced Research Projects Agency (DARPA), Broad Agency Announcement, Defense Sciences Research & Technology. Medicago USA received the grant to demonstrate the scalable manufacturing of its plant-expressed VLP vaccines in the US under a technology investment agreement.
The company will develop a 90,000-square-foot cGMP facility in Research Triangle Park (RTP), NC. This will be a scaled-up facility for Medicago’s VLP plant–based vaccine technology for the delivery of cGMP-grade vaccine. Medicago will scale-up and automate its cGMP process to demonstrate its capacity to produce 10 million doses per month of influenza vaccines with the potential for further expansion in the future.
During the recent H1N1 influenza outbreak, Medicago was able to develop a vaccine candidate through its plant-based VLP vaccine technology in less than a month after the H1N1 strain was identified.
This DARPA project is an accelerated and integrated effort to deliver effective production of pandemic influenza in the US. Its Accelerated Manufacture of Pharmaceuticals program seeks to identify new ways to produce large amounts of vaccine protein in less than three months in response to emerging and novel biologic threats. The strategic collaboration is a $42 million project in which DARPA contributes $21 million, Medicago $7.5 million, and Alexandria Real Estate Equities Inc. $13.5 million.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
